Weekly News Recap #Phispers
Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down
This week saw Eli Lilly strike yet another deal as it announced the acquisition of Morphic Holding for about US$ 3.2 billion, t...
Impressions : 1364
Court dismisses Astra’s lawsuit over IRA price talks; Ozempic shows benefits to kidney, heart in diabetics with CKD
This week’s Phispers brings updates on the Inflation Regulation Act (IRA) in the US. A federal district court judge rejec...
Impressions : 1146
Sanofi, Roche, Sobi, Avantor – a big week for M&As; JAK inhibitors to carry heart safety, cancer warnings
This week, Phispers brings you news on Pfizer’s Xeljanz, which underwent a post-approval study. Post the study, the ...
Impressions : 2244
Trump admin wants to pull global supply chains out of China; FDA okays remdesivir for emergency use
This week, Phispers has news on remdesivir, Gilead’s investigational antiviral drug.
The USFDA has issued an emergency ...
Impressions : 67089
FDA releases GDUFA II fee for FY20; Teva to recover settlement charge from execs
This week, the USFDA released its GDUFA II user fee for fiscal 2020.
Unlike last year, when the fees were hiked significantly...
Impressions : 1676
Aurobindo’s sartan banned in Europe; Dr. Reddy’s cost optimization drive continues, sells off another site
This week, Phispers brings you news from Dr. Reddy’s Laboratories in India which is divesting its API plant in Hyderabad ...
Impressions : 3869
Teva to exit 80 percent generics portfolio in US; Takeda clinches Shire for US$ 62 billion
This week in Phispers, we report on the biggest deal of 2018 yet — Takeda’s acquisition of Shire — that would...
Impressions : 6509
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.